Skip to search formSkip to main contentSkip to account menu

turoctocog alfa

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Factor VIII (FVIII) is indicated for the prevention or treatment of bleeding in patients with hemophilia A. FVIII product… 
Review
2015
Review
2015
Summary Turoctocog alfa (NovoEight®) is a new recombinant factor VIII (rFVIII) with a truncated B domain and a high degree of… 
Review
2014
Review
2014
Hemophilia A (HA) represents one of the most common genetic bleeding disorders worldwide and results from a deficiency in factor…